A novel self-assemble peptide drug design of AKT1 for anaplastic thyroid cancer therapy
Authors:
Open Access
- 15 April 2022
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 611, 19-22
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 17 references indexed in Scilit:
- Thyroid cancerThe Lancet, 2016
- Low-Level Laser Therapy Promoted Aggressive Proliferation and Angiogenesis Through Decreasing of Transforming Growth Factor-β1 and Increasing of Akt/Hypoxia Inducible Factor-1α in Anaplastic Thyroid CancerPhotomedicine and Laser Surgery, 2016
- Low risk papillary thyroid cancerBMJ, 2014
- Anaplastic thyroid cancerOral Oncology, 2013
- American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid CancerThyroid®, 2012
- Akt signalling in health and diseaseCellular Signalling, 2011
- Anaplastic thyroid cancer: molecular pathogenesis and emerging therapiesEndocrine-Related Cancer, 2009
- Anaplastic thyroid carcinoma: An overviewCurrent Oncology Reports, 2007
- Strategies to improve plasma half life time of peptide and protein drugsAmino Acids, 2006
- PI3K/Akt signalling pathway and cancerCancer Treatment Reviews, 2004